Kobayashi Pharmaceutical is considering taking its shares private, and has received acquisition proposals from NSSK and UK-based VC Capital Partners. The proposals are preliminary and non-binding, and no decision has been made as of now.
Kobayashi Pharmaceutical is considering taking its shares private after receiving acquisition proposals from NSSK (Nippon Sangyo Suishin Kiko) and UK-based VC Capital Partners, according to people familiar with the matter. The proposals were presented as one option for enhancing the company’s value and are reportedly at a preliminary stage without legal binding force.
Kobayashi Pharmaceutical said it had in fact received the proposals, but commented that, as of the time of reporting, no official decision had been made. No formal decision or future policy has been disclosed at this point.
According to people familiar with the matter, taking the company private has been cited as one possible way of maximizing shareholder value, and the acquisition proposals themselves are expected to remain one option in the course of future consideration. Their non-binding nature is considered a defining feature.
Several media outlets reporting on the matter have conveyed the existence of the proposals and the status of the company’s consideration in broadly similar terms. It remains to be seen whether additional official announcements or information will be released.